Shanghai Henlius jumps most in 3-1/2 months on tumour drug trial approval

Shanghai Henlius Biotech

28/01/2026 07:00

** Shanghai Henlius Biotech 2696.HK stock surges 7.7% to HK$58.8, set for biggest one-day gain since Oct 8

** Stock hits highest level since Jan 23, snapping 7-session losing streak

** China's drug regulator approves clinical trial for antibody-drug conjugate HLX43 combined with monoclonal antibody HLX07 for advanced solid tumours, co says

** Company says it intends to commence the relevant clinical trials in mainland China when conditions are met

** YTD, stock up 2.1%, Hang Seng Biotech Index .HSBIO up 11.8%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))